IP Library Granted Patent US 12679901
Granted Patent B2
US 12679901 · App. 17/861,196 · Granted Jul 14, 2026

Anti-TLR7 agents and compositions and methods for making and using the same

Inventors: Takatoku Oida (San Diego, CA); Anagha Ashok Divekar (San Diego, CA); Shawna Ann Shirley (San Diego, CA); Nicole Vivienne Acuff (San Diego, CA)
Assignee: BioLegend, Inc.
C07K16/2896G01N33/6872C07K2317/24C07K2317/565C07K2317/567C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679901
App. No.
17/861,196
Granted
Jul 14, 2026
Kind
B2
Abstract

Compositions and methods for making and using anti-TLR7 agents, for example, monoclonal antibodies, TLR7-binding antibody fragments, and derivatives are described, as are kits, nucleic acids encoding such molecules, diagnostic reagents and kits that include anti-TLR7 agents, and methods of making and using the same.

Claims (108)

1 . An anti-TLR7 agent that binds Toll-like Receptor 7 (TLR7), comprising an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain, wherein the immunoglobulin heavy chain variable domain comprises a set of CDRH1, CDRH2, and CDRH3 amino acid sequences and the immunoglobulin light chain variable domain comprises a set of CDRL1, CDRL2, and CDRL3 amino acid sequences, wherein the amino acid sequences for the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain comprise sequences selected from one of sets 1-6:

CDRH1

CDRH2

CDRH3

CDRL1

CDRL2

CDRL3

set

(SEQ ID NO:)

(SEQ ID NO:)

(SEQ ID NO:)

(SEQ ID NO:)

(SEQ ID NO:)

(SEQ ID NO:)

1

DYWMS (1)

DIKYDGSFID

DLTTVVDGFAY

RASQSLSTSI

YASQPIS (24)

QQSYSSPYT

YAPSLKN (6)

(12)

H (19)

(29)

2

DYWMS (1)

DIKYDGTFI

DLTTVVDGFAY

RASQSLSTSI

YASQPIS (24)

QQSYSSPYT

DYAPSLKN

(12)

H (19)

(29)

(7)

3

NYYMA (2)

SITNSGRTTY

EGGDLYYSN

LPSEDIYNN

YASNLQD

LQDSDYPFT

YRDSVKG

YNYVRFAY

LA (18)

(23)

(28)

(8)

(13)

4

DYYMA (3)

SISYEGSSTH

HGGYPNWYFDF

RASEDIYNE

NANSLHT

QQYYDYPW

YGDSVKA

(14)

LA (17)

(22)

T (27)

(9)

5

DYCVH (4)

YINPYSGYT

GPYGGYSGDGFDY

RASEDIYNV

NANRLHN

QQYYDYPN

NYNEKFKS

(15)

LA (16)

(20)

T (25)

(10)

6

DYYIH (5)

FINPDSGYT

GPYGGYSGDGFDY

RASEDIYNV

NANNLHT

QQYYDYPH

NYNEKFKT

(15)

LA (16)

(21)

T (26)

and wherein all CDR amino acid sequences are from the same set.

2 . The anti-TLR7 agent of claim 1 , wherein the amino acid sequences for the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain are selected from set 1.

3 . The anti-TLR7 agent of claim 1 , wherein the amino acid sequences for the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain are selected from set 2.

4 . The anti-TLR7 agent of claim 1 , wherein the amino acid sequences for the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain are selected from set 3.

5 . The anti-TLR7 agent of claim 1 , wherein the immunoglobulin heavy chain variable domain (VH) comprises at least 90% identity to the sequence set forth in any one of SEQ ID NOS: 36-41.

6 . The anti-TLR7 agent of claim 1 , wherein the immunoglobulin heavy chain variable domain (VH) comprises at least 90% identity to the sequence set forth in SEQ ID NO:41.

7 . The anti-TLR7 agent of claim 1 , wherein the immunoglobulin light chain variable region comprises at least 90% identity to a sequence set forth in any of SEQ ID NOS: 42-47.

8 . The anti-TLR7 agent of claim 1 , wherein the immunoglobulin light chain variable region comprises at least 90% identity to a sequence set forth in SEQ ID NO:47.

9 . The anti-TLR7 agent of claim 1 , comprising two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains.

10 . The anti-TLR7 agent of claim 1 , wherein the agent comprises an antibody, or antigen-binding fragment thereof.

11 . The anti-TLR7 agent of claim 1 , wherein the agent comprises a humanized antibody, or a humanized antigen binding fragment thereof.

12 . The anti-TLR7 agent of claim 1 , further comprising one or more human framework regions.

13 . The anti-TLR7 agent of claim 1 , wherein the agent is conjugated to a detectable marker or label.

14 . The anti-TLR7 agent of claim 1 , wherein the agent is non-diffusively immobilized on a solid support.

15 . A diagnostic reagent comprising the anti-TLR7 agent of claim 1 .

16 . A kit comprising the anti-TLR7 agent of claim 1 .

17 . The anti-TLR7 agent of claim 1 , wherein the amino acid sequences for the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain are selected from set 4.

18 . The anti-TLR7 agent of claim 1 , wherein the amino acid sequences for the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain are selected from set 5.

19 . The anti-TLR7 agent of claim 1 , wherein the amino acid sequences for the immunoglobulin heavy chain variable domain and the immunoglobulin light chain variable domain are selected from set 6.